Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.58 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.58 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GUSB | P08236 | 2/20 | 0.42 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532370 | 0.98 | GNAO1 (0.55) | GNAO1GNAI3GNAI1KCNH2GUSB | |
| SCHEMBL27756873 | 0.92 | GNAO1 (0.47) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL17351087 | 0.89 | GNAO1 (0.50) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL6920677 | 0.87 | GNAO1 (0.47) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL16625896 | 0.86 | GNAI3 (0.42) | GNAO1GNAI3GNAI1 | |
| SCHEMBL13167818 | 0.84 | HRH3 (0.45) | GNAO1GNAI3GNAI1 | |
| SCHEMBL28863184 | 0.83 | GNAO1 (0.40) | GNAO1GNAI3GNAI1 | |
| SCHEMBL30379435 | 0.81 | GNAI3 (0.41) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL9869321 | 0.81 | GNAI3 (0.41) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL19711120 | 0.81 | GUSB (0.53) | GNAO1GNAI3GNAI1GUSBEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| CN-114085212-B | Isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-05-02 | — | — | CN | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | GNAO1 3397/4885GNAI3 1467/4885GNAI1 1872/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | GNAO1 3397/4885GNAI3 1467/4885GNAI1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.